Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Biotech
Merus hails 'unprecedented' survival on solid tumor bispecific
Merus reported a 79% 12-month survival rate, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.”
Nick Paul Taylor
May 23, 2025 7:35am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
'One of the lucky few': Bicara CEO on last year's $326M IPO
Apr 14, 2025 3:59pm
Avacta hits 10% response rate, adds peptide-drug conjugate arms
Jan 16, 2025 8:51am
Merus touts cancer drug's strong profile with new data drop
Dec 2, 2024 11:59am
